{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:44:12Z","timestamp":1789731852077,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mater Sci: Mater Med"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chagas disease is a neglected tropical disease caused by the flagellate protozoan <jats:italic>Trypanosoma cruzi<\/jats:italic> (<jats:italic>T. cruzi<\/jats:italic>). Endemic in underdeveloped and developed countries, due to the migratory movement, it is considered a serious public health problem. Endemic in underdeveloped countries and due to the migratory movement, in developed countries as well, it is considered a serious public health problem. One of the reasons for this is a weak therapeutic arsenal, represented only by the drug benznidazole (BNZ) which, although it promotes significant cure rates in the acute phase of the disease, presents serious problems of toxicity and bioavailability, mainly due to its low aqueous solubility. Several studies have presented several drug delivery systems (DDS) based on BNZ aiming at enhancing its solubility in aqueous medium and, with this, promoting an increase in the dissolution rate and, consequently, in its bioavailability. However, the present work is a pioneer in using a zeolitic imidazolate framework as a carrier agent for a DDS in order to promote a pH-sensitive modulation of the drug. Thus, this work aimed to develop a novel DDS based on BNZ and the ZIF-8 to use it in development of prolonged-release dosage forms to alternative treatment of Chagas disease. The BNZ@ZIF-8 system was obtained through an ex situ method selected due to its higher incorporation efficiency (38%). Different characterization techniques corroborated the obtainment and drug release data were analyzed by in vitro dissolution assay under sink and non-sink conditions and setting the kinetic results through both model dependent and independent methods. Under sink conditions, at pH 4.5, BNZ and BNZ@ZIF-8 showed similar release profile, but the DDS was effective in promoting a prolonged release. At pH 7.6, after 7\u2009h, BNZ showed a lower release than BNZ@ZIF-8. On the other hand, in non-sink conditions at pH 4.5 the BNZ presented 80% of drug release in 3\u2009h, while the DDS in 6\u2009h. At pH 7.6, BNZ presented a release of 80% in 2\u2009h, while the DDS reaches it in only at 12\u2009h. Therefore, at pH 4.5 the DDS BNZ@ZIF-8 showed a faster release with a burst effect, while at pH 7.6 it showed a prolonged and controlled release. Finally, it is evident that a promising DDS pH-sensitive was obtained as a novel carrier that might be able to prolongs BNZ release in dosage forms intended for the alternative treatment of Chagas disease.<\/jats:p>","DOI":"10.1007\/s10856-021-06530-w","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T10:03:16Z","timestamp":1621245796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Benznidazole in vitro dissolution release from a pH-sensitive drug delivery system using Zif-8 as a carrier"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5100-2554","authenticated-orcid":false,"given":"Leslie Raphael","family":"de Moura Ferraz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alinne \u00c9lida Gon\u00e7alves Alves","family":"Tabosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora Dolores Souza","family":"da Silva Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline Silva","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Yago Rodrigues","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severino Alves","family":"Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Ara\u00fajo","family":"Rolim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Jose","family":"Rolim-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"6530_CR1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1590\/0074-02760150153","volume":"110","author":"JR Coura","year":"2015","unstructured":"Coura JR, Junqueira ACV. Surveillance, health promotion and control of Chagas disease in the Amazon Region - Medical attention in the Brazilian Amazon Region: a proposal. Mem Inst Oswaldo Cruz. 2015;110:825\u201330.","journal-title":"Mem Inst Oswaldo Cruz."},{"key":"6530_CR2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/S0104-59702009000500002","volume":"16","author":"SP Kropf","year":"2009","unstructured":"Kropf SP, S\u00e1 MR. The discovery of Trypanosoma cruzi and Chagas disease (1908\u20131909): tropical medicine in Brazil. Histo\u0301ria, Cie\u0302ncias, Sau\u0301de-Manguinhos. 2009;16:13\u201334.","journal-title":"Histo\u0301ria, Cie\u0302ncias, Sau\u0301de-Manguinhos"},{"key":"6530_CR3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.actatropica.2013.04.003","volume":"127","author":"JA P\u00e9rez-Molina","year":"2013","unstructured":"P\u00e9rez-Molina JA, Sojo-Dorado J, Norman F, Monge-Maillo B, D\u00edaz-Men\u00e9ndez M, Albajar-Vi\u00f1as P, et al. Nifurtimo x therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment. Acta Trop. 2013;127:101\u20134.","journal-title":"Acta Trop"},{"key":"6530_CR4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5216\/rpt.v36i2.1783","volume":"36","author":"JL Soares Sobrinho","year":"2007","unstructured":"Soares Sobrinho JL, Medeiros FPM, La Roca MF, Silva KER, Lima LNA, Rolim-Neto PJ. Delineamento de alternativas terap\u00eauticas para o tratamento da doen\u00e7a de Chagas. Rev Patol Trop. 2007;36:103\u201318.","journal-title":"Rev Patol Trop"},{"key":"6530_CR5","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1590\/0074-0276140156","volume":"109","author":"B Zingales","year":"2014","unstructured":"Zingales B, Miles MA, Moraes CB, Luquetti A, Guhl F, Schijman AG, et al. Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity. Mem Inst Oswaldo Cruz. 2014;109:828\u201333.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"6530_CR6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1590\/S0036-46652002000100006","volume":"44","author":"JR Can\u00e7ado","year":"2002","unstructured":"Can\u00e7ado JR. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop. 2002;44:29\u201337.","journal-title":"Rev Inst Med Trop"},{"key":"6530_CR7","first-page":"209","volume":"37","author":"MF Oliveira","year":"2008","unstructured":"Oliveira MF, Nagao-Dias AT, Pontes VMO, Souza-J\u00fanior AS, Coelho HLL, Coelho ICB. Tratamento etiol\u00f3gico da doen\u00e7a de Chagas no Brasil. Rev Patol Trop. 2008;37:209\u201328.","journal-title":"Rev Patol Trop"},{"key":"6530_CR8","first-page":"1","volume":"27","author":"JC Villar","year":"2014","unstructured":"Villar JC, Perez PG, Cortes OL, Riarte A, Pepper M, Marin-Neto JA, et al. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev. 2014;27:1\u201371.","journal-title":"Cochrane Database Syst Rev"},{"key":"6530_CR9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijpharm.2014.06.015","volume":"472","author":"R Palmeiro-Rold\u00e1n","year":"2014","unstructured":"Palmeiro-Rold\u00e1n R, Fonseca-Berzal C, G\u00f3mez-Barrio A, Ar\u00e1n VJ, Escario JA, Torrado-Dur\u00e1n S, et al. Development of novel benznidazole formulations: physicochemical characterization and in vivo evaluation on parasitemia reduction in Chagas disease. Int J Pharm. 2014;472:110\u20137.","journal-title":"Int J Pharm"},{"key":"6530_CR10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.exppara.2014.03.013","volume":"140","author":"A Trochine","year":"2014","unstructured":"Trochine A, Alvarez G, Corre S, Faral-Tello P, Dur\u00e1n R, Batthyany CI, et al. Trypanosoma cruzi chemical proteomics using immobilized benznidazol. Exp Parasitol. 2014;140:33\u201338.","journal-title":"Exp Parasitol"},{"key":"6530_CR11","first-page":"941","volume":"6","author":"K Adibkia","year":"2012","unstructured":"Adibkia K, Alaei-beirami M, Barzegar-jalali M, Mohammadi G, Ardestani MS. Evaluation and optimization of factors affecting novel diclofenac sodium-eudragit RS100 nanoparticles. Afr J Pharm Pharmacol. 2012;6:941\u20137.","journal-title":"Afr J Pharm Pharmacol."},{"key":"6530_CR12","first-page":"1","volume":"2","author":"Y Lu","year":"2016","unstructured":"Lu Y, Aimetti A, Langer R, Gu Z. Bioresponsive materials. Nat Rev Mats. 2016;2:1\u201317.","journal-title":"Nat Rev Mats"},{"key":"6530_CR13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.memsci.2014.09.040","volume":"474","author":"M Fang","year":"2015","unstructured":"Fang M, Wu C, Yang Z, Wang T, Xia Y, Li J. ZIF-8\/PDMS mixed matrix membranes for propane\/nitrogen mixture separation: Experimental result and permeation model validation. J Memb Sci. 2015;474:103\u201313.","journal-title":"J Memb Sci"},{"key":"6530_CR14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.micromeso.2015.02.049","volume":"211","author":"RL Papporello","year":"2015","unstructured":"Papporello RL, Mir\u00f3 EE, Zamaro JM. Secondary growth of ZIF-8 films onto copper-based foils. Insight into surface interactions. Microporous Mesoporous Mater. 2015;211:64\u201372.","journal-title":"Microporous Mesoporous Mater"},{"key":"6530_CR15","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1039\/c2ce26847g","volume":"15","author":"K Kida","year":"2013","unstructured":"Kida K, Okita M, Fujita K, Tanaka S, Miyake Y. Formation of high crystalline ZIF-8 in an aqueous solution. Cryst Eng Comm. 2013;15:1794\u2013801.","journal-title":"Cryst Eng Comm"},{"key":"6530_CR16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.cbpa.2009.12.012","volume":"14","author":"RC Huxford","year":"2010","unstructured":"Huxford RC, Della Rocca J, Lin W. Metal\u2013organic frameworks as potential drug carriers. Curr Opin Chem Biol. 2010;14:262\u20138.","journal-title":"Curr Opin Chem Biol."},{"key":"6530_CR17","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1002\/1521-3765(20011203)7:23<5168::AID-CHEM5168>3.0.CO;2-S","volume":"7","author":"M Edgar","year":"2001","unstructured":"Edgar M, Mitchell R, Slawin AMZ, Lightfoot P, Wright PA. Solid-State Transformations of Zinc 1,4-Benzenedicarboxylates Mediated by Hydrogen-Bond-Forming Molecules. Chem Eur J. 2001;7:5168\u201375.","journal-title":"Chem Eur J"},{"key":"6530_CR18","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1021\/nn406590q","volume":"8","author":"J Zhuang","year":"2014","unstructured":"Zhuang J, Kuo CH, Chou LY, Liu DY, Weerapana E, Tsung CK. Optimized metal-organic-framework nanospheres for drug delivery: evaluation of small-molecule encapsulation. ACS Nano. 2014;8:2812\u20139.","journal-title":"ACS Nano"},{"key":"6530_CR19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.micromeso.2016.07.012","volume":"234","author":"X Yan","year":"2016","unstructured":"Yan X, Yang Y, Hu X, Zhou M, Komarneni S. Synthesis of mesoporous carbons with narrow pore size distribution from metal-organic framework MIL-100(Fe). Micro Meso Mat. 2016;234:162\u20135.","journal-title":"Micro Meso Mat"},{"key":"6530_CR20","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1021\/acs.molpharmaceut.5b00043","volume":"12","author":"C Adhikari","year":"2015","unstructured":"Adhikari C, Das A, Chakraborty A. Zeolitic imidazole framework (ZIF) nanospheres for easy encapsulation and controlled release of an anticancer drug doxorubicin under different external stimuli: a way toward smart drug delivery system. Mol Pharm. 2015;12:3158\u201366.","journal-title":"Mol Pharm"},{"key":"6530_CR21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nmat2608","volume":"9","author":"P Horcajada","year":"2010","unstructured":"Horcajada P, Chalati T, Serre C, Gillet B, Sebrie C, Baati T, et al. Porous metal\u2013organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat Mat. 2010;9:172\u20138.","journal-title":"Nat Mat"},{"key":"6530_CR22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/03639045.2013.845842","volume":"41","author":"FL Santos","year":"2015","unstructured":"Santos FL, Rolim LA, Figueir\u00eado CB, Lyra MA, Peixoto MS, Ferraz LR, et al. A study of photostability and compatibility of the anti-chagas drug Benznidazole with pharmaceutics excipients. Drug Dev Ind Pharm. 2015;41:63\u201369.","journal-title":"Drug Dev Ind Pharm"},{"key":"6530_CR23","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1021\/am301365h","volume":"4","author":"N Li\u00e9dana","year":"2012","unstructured":"Li\u00e9dana N, Galve A, Rubio C, T\u00e9llez C, Coronas J. CAF@ZIF-8: one-step encapsulation of caffeine in MOF. ACS Appl Mater Interfaces. 2012;4:5016\u201321.","journal-title":"ACS Appl Mater Interfaces"},{"key":"6530_CR24","doi-asserted-by":"crossref","first-page":"9437","DOI":"10.1039\/c2ra21087h","volume":"2","author":"IB Vasconcelos","year":"2012","unstructured":"Vasconcelos IB, Silva TG, Milit\u00e3o GCG, Soares TA, Rodrigues NM, Rodrigues MO, et al. Cytotoxicity and slow release of the anti-cancer drug doxorubicin from ZIF-8. RSC Adv. 2012;2:9437\u201342.","journal-title":"RSC Adv"},{"key":"6530_CR25","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1039\/c4ce90043j","volume":"16","author":"L He","year":"2014","unstructured":"He L, Wang T, An J, Li X, Zhang L, Li L, et al. Carbon nanodots@zeolitic imidazolate framework-8 nanoparticles for simultaneous pH-responsive drug delivery and fluorescence imaging. Cryst Eng Comm. 2014;16:3237\u2013440.","journal-title":"Cryst Eng Comm"},{"key":"6530_CR26","doi-asserted-by":"crossref","first-page":"10186","DOI":"10.1073\/pnas.0602439103","volume":"103","author":"KS Park","year":"2006","unstructured":"Park KS, Ni Z, Cote AP, Choi JY, Huang RD, Uribe-Romo FJ, et al. Exceptional chemical and thermal stability of zeolitic imidazolate frameworks. Proc Natl Acad Sci USA. 2006;103:10186\u201391.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6530_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14227\/DT080301P6","volume":"8","author":"BR Rohrs","year":"2001","unstructured":"Rohrs BR. Dissolution method development for poorly soluble compounds. Dissolution Technol. 2001;8:1\u20135.","journal-title":"Dissolution Technol"},{"key":"6530_CR28","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1590\/S0100-40422007000500021","volume":"30","author":"ALM Silva","year":"2007","unstructured":"Silva ALM, Soares-Sobrinho JL, Rolim-Neto PJ, Silva RMF, Medeiros FPM, Lima LG. Desenvolvimento de m\u00e9todo anal\u00edtico por CLAE em comprimidos de benznidazol para a doen\u00e7a de Chagas. Quim Nova. 2007;30:1163\u20136.","journal-title":"Quim Nova"},{"key":"6530_CR29","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/jps.2600821126","volume":"82","author":"H Aronson","year":"1993","unstructured":"Aronson H. Correction factor for dissolution profile calculations. J Pharm Sci. 1993;82:1190.","journal-title":"J Pharm Sci"},{"key":"6530_CR30","first-page":"196","volume":"59","author":"S Singh","year":"1997","unstructured":"Singh S, Kaur B, Singh T. Correction of raw disolution data for loss of drug during sampling. Indian J Pharm Sci. 1997;59:196\u20139.","journal-title":"Indian J Pharm Sci"},{"key":"6530_CR31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","volume":"12","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12:263\u201371.","journal-title":"AAPS J"},{"key":"6530_CR32","first-page":"217","volume":"67","author":"S Dash","year":"2010","unstructured":"Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67:217\u201323.","journal-title":"Acta Pol Pharm"},{"key":"6530_CR33","volume-title":"Farmacop\u00e9ia Brasileira, 5\u00b0 Edi\u00e7\u00e3o, volume 1","author":"Brasil.","year":"2010","unstructured":"Brasil. Farmacop\u00e9ia Brasileira, 5\u00b0 Edi\u00e7\u00e3o, volume 1. Bras\u00edlia: Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria; 2010."},{"key":"6530_CR34","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1021\/mp800042d","volume":"5","author":"JC Dinunzio","year":"2008","unstructured":"Dinunzio JC, Miller DA, Yang W, McGinity JW, Williams RO. Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. Mol Pharm. 2008;5:968\u201380.","journal-title":"Mol Pharm"},{"key":"6530_CR35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0378-5173(89)90306-2","volume":"57","author":"NA Peppas","year":"1989","unstructured":"Peppas NA, Sahlin JJ. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int J Pharm. 1989;57:169\u201372.","journal-title":"Int J Pharm"},{"key":"6530_CR36","doi-asserted-by":"crossref","unstructured":"Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25\u201335.","DOI":"10.1016\/0378-5173(83)90064-9"},{"key":"6530_CR37","unstructured":"Alves IVB. Metal-Organic Frameworks (MOFs): Alternativa Inteligente Para Carreamento de F\u00e1rmacos Anti-Inflamat\u00f3rio E Antineopl\u00e1sico [Dissertation]. Recife: Universidade Federal de Pernambuco; 2013."},{"key":"6530_CR38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejpb.2011.12.016","volume":"81","author":"DD Sun","year":"2012","unstructured":"Sun DD, Ju TCR, Lee PI. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels. Eur J Pharm Biopharm. 2012;81:149\u201358.","journal-title":"Eur J Pharm Biopharm"},{"key":"6530_CR39","first-page":"122","volume":"37","author":"P Steingr\u00e4ber","year":"2008","unstructured":"Steingr\u00e4ber P, Schtoltz T, Rodrigues PO. Evaluation of soluble non-polymeric adjuvants in the release of nimodipino from controlled release matrices formulations. Rev Colomb Cienc Qu\u00edm Farm. 2008;37:122\u201332.","journal-title":"Rev Colomb Cienc Qu\u00edm Farm"},{"key":"6530_CR40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/2231-4040.85534","volume":"2","author":"G Arora","year":"2011","unstructured":"Arora G, Malik K, Singh I, Arora S, Rana V. Formulation and evaluation of controlled release matrix mucoadhesive tablets of domperidone using Salvia plebeian gum. J Adv Pharm Technol Res. 2011;2:163\u20139.","journal-title":"J Adv Pharm Technol Res"},{"key":"6530_CR41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1590\/S1984-82502014000300007","volume":"50","author":"I Khalid","year":"2014","unstructured":"Khalid I, Ahmad M, Minhas MU, Sohail M. Formulation and in vitro evaluation of mucoadhesive controlled release matrix tablets of flurbiprofen using response surface methodology. Braz J Pharm Sci. 2014;50:493\u2013504.","journal-title":"Braz J Pharm Sci"},{"key":"6530_CR42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1590\/0037-8682-0248-2013","volume":"47","author":"JCP Dias","year":"2014","unstructured":"Dias JCP, Coura JR, Yasuda MAS. The present situation, challenges, and perspectives regarding the production and utilization of effective drugs against human Chagas disease. Rev Soc Bras Med Trop. 2014;47:123\u20135.","journal-title":"Rev Soc Bras Med Trop."},{"key":"6530_CR43","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.4049\/jimmunol.1102053","volume":"188","author":"I Cestari","year":"2012","unstructured":"Cestari I, Ansa-Addo E, Deolindo P, Inal JM, Ramirez RM. Trypanosoma cruzi Immune Evasion Mediated by Host Cell-Derived Microvesicles. J Immunol. 2012;188:1942\u201352.","journal-title":"J Immunol"},{"key":"6530_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2013.00002","volume":"4","author":"W Souza","year":"2013","unstructured":"Souza W, Carvalho TMU. Active penetration of Trypanosoma cruzi into host cells: historical considerations and current concepts. Front Immunol. 2013;4:1\u20133.","journal-title":"Front Immunol"},{"key":"6530_CR45","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1039\/C3CC47666A","volume":"50","author":"H Ren","year":"2014","unstructured":"Ren H, Zhang L, An J, Wang T, Li L, Si X, et al. Polyacrylic acid@zeolitic imidazolate framework-8 nanoparticles with ultrahigh drug loading capability for pH-sensitive drug release. Chem Commun. 2014;50:1000\u20132.","journal-title":"Chem Commun"},{"key":"6530_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73848-w.","volume":"10","author":"LRM Ferraz","year":"2020","unstructured":"Ferraz LRM, Tabosa AEGA, Nascimento DDSS, Ferreira AS, Sales VAW, Silva JYR, et al. ZIF\u20118 as a promising drug delivery system for benznidazole: development, characterization, in vitro dialysis release and cytotoxicity. Sci Rep. 2020;10:16815. https:\/\/doi.org\/10.1038\/s41598-020-73848-w.","journal-title":"Sci Rep"},{"key":"6530_CR47","doi-asserted-by":"publisher","unstructured":"Xia Y, Hong Y, Geng R, Li X, Qu A, Zhou Z, et al. Amine-functionalized ZIF-8 as a fluorescent probe for breath volatile organic compound biomarker detection of lung cancer patients. ACS Omega. 2020;5:3478\u201386. https:\/\/doi.org\/10.1021\/acsomega.9b03793.","DOI":"10.1021\/acsomega.9b03793"}],"container-title":["Journal of Materials Science: Materials in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10856-021-06530-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10856-021-06530-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10856-021-06530-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T08:06:34Z","timestamp":1624521994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10856-021-06530-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["6530"],"URL":"https:\/\/doi.org\/10.1007\/s10856-021-06530-w","relation":{},"ISSN":["0957-4530","1573-4838"],"issn-type":[{"value":"0957-4530","type":"print"},{"value":"1573-4838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"59"}}